Latest News
FDA approves Merck's Keytruda combinations for first-line treatment of PD-L1-positive advanced triple-negative breast cancer
25 June 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Thursday that the US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizuma...
Ionis licenses ex-US rights to zilganersen for Alexander disease to Recordati
25 June 2026 - Biotechnology company Ionis Pharmaceuticals Inc (Nasdaq:IONS) said on Thursday that it has entered into a licensing agreement granting Recordati exclusive rights to develop and commercialise zilganersen for Alexander disease (AxD) in a...
Dicot Pharma receives FDA clearance to start Phase 2b study of LIB-01 in US
25 June 2026 - Swedish pharmaceutical company Dicot Pharma AB (Nasdaq First North:DICOT) said on Thursday that it has received clearance from the US Food and Drug Administration (FDA) to initiate Part I of its Phase 2b study for LIB-01, an investigat...
CeleCor Therapeutics submits final section of zalunfiban (Disaggpro) New Drug Application to US FDA
25 June 2026 - US pharmaceutical company CeleCor Therapeutics said on Wednesday that it has submitted the final section of its New Drug Application (NDA) for the company's investigational heart-attack drug, zalunfiban (Disaggpro), to the US Food...
Biosidus partners with Mubadala Bio in the UAE
25 June 2026 - Biosidus, an Argentina-based biotechnology company, announced on Wednesday the signing of a licensing and supply agreement with Mubadala Bio, the life sciences platform of Mubadala Investment Company, to introduce a portfolio of biolog...